Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control

Table 3

EWOC with Covariate. Design operating characteristic with respect to safety and efficiency of the trial.

𝛾0=𝛾1	0.2	0.4	0.6	0.8
Proportion of DLTs	0.3337	0.2721	0.2183	0.1759
Proportion of DLTs in group A	0.3319	0.2751	0.2222	0.1764
Proportion of DLTs in group B	0.3356	0.2691	0.2143	0.1754
Proportion overdosed in group A	0.3361	0.1790	0.04995	0.0008
Proportion overdosed in group B	0.3346	0.1802	0.0497	0.0010
Bias (𝛾1)	−0.0134	−0.0387	−0.0965	−0.2002
MSE (𝛾1)	0.0716	0.1373	0.2142	0.3425